(thirdQuint)Phase II Trial of SBRT + or - IMRT in Treatment of Patients With Clinically Confined Prostate Adenocarcinoma.

 Patients with locally confined prostate adenocarcinoma (clinical stage T1c - T2bN0M0, Gleason score 7, PSA 20 ng/ml) are assigned to one of two treatment arms.

 Low risk patients (T1c-T2a and PSA 10 ng/ml orGleason Score 7) will receive 1.

8 Gy of IMRT for 25 fractions over 5 weeks for a total of 45 Gy.

 They will then receive a boost consisting of 4, 5.

5 Gy fractions after IMRT for a total of 22 Gy.

 All patients will be assessed for toxicity at periodic time points following completion of treatment.

.

 Phase II Trial of SBRT + or - IMRT in Treatment of Patients With Clinically Confined Prostate Adenocarcinoma@highlight

Patients with locally confined prostate adenocarcinoma (clinical stage T1c - T2bN0M0, Gleason score 7, PSA 20 ng/ml) are assigned to one of two treatment arms.

 Low risk patients (T1c-T2a and PSA 10 ng/ml orGleason Score 7) will receive 1.

8 Gy of IMRT for 25 fractions over 5 weeks for a total of 45 Gy.

 They will then receive a boost consisting of 4, 5.

5 Gy fractions after IMRT for a total of 22 Gy.

